Abstract 2756
Background
Malign obstructive jaundice (MOJ) in cancer is due to liver metastasis and/or biliary duct compression. Percutaneous biliary drainage (PBD) is a palliative procedure. Prognostic & predictive factors are needed for selection of the cancer patients who will get more benefit from PBD in MOJ. We evaluated cancer patients (CP) who had PBD for MOJ for clinicopathological features (CPF) & survival outcomes besides potential predictive markers for PBD.
Methods
110 CP who had PBD for MOJ between 2010 & 2016 were evaluated retrospectively. The correlation between biochemical values, CPF (extrahepatic metastasis (EM), obstruction cause (OC), stent localization) & total bilirubin (TB) was evaluated by ROC analysis. The CP were analyzed according to TB after PBD [groups A: normal (1 mg/dl or 20% decrease), C: stable/increase.
Results
Median age was 60 (28-82) years. 57 were male. In univariate analysis, EM & OC were significant factors with concordance to biochemical values. Albumin (p = 0.007, OR: 5.2, 1,5-17,1), LDH (p = 0.041, OR:2.5, 1.02-6,2) & OC (p = 0.019, OR:3.4, 1.2-9,9) remained significant in multivariate analysis. The CP were grouped according to these risk factors (RF): groups 1 (22,7%: no RF), 2 (64,5%: 1-2 RF), 3 (12,7%: >3 RF). TB normalization & OS after PBD are shown in table 1. Stenting proximal to choledoc had better TB normalization (44,7% vs 17,6%, p = 0.006).Chemotherapy rates were as 60% for group A, 36,8% for group B & 21,9% for group C (p = 0.004). 6-months OS was 41,3% for patients receiving chemotherapy & 17,7% for others (p
Conclusions
| Group A* (%) | Group A* (%) OS | |
|---|---|---|
| Total bilirubin (mg/dl) | ||
| >13 | 19,6 | 18,5 |
| 2,5 | 12,1 | 6 |
Clinical trial identificationLegal entity responsible for the studyN/A FundingN/A DisclosureAll authors have declared no conflicts of interest. Resources from the same sessionZUMA-3: A phase 1/2 multi-center study evaluation the safety and efficacy of KTE-C19 anti-CD19 CAR T cells in adult patients with relapsed/refractory B precursor acute lymphoblastic leukemia (R/R ALL)Presenter: Bijal Shah Session: Poster display Resources: Abstract ZUMA-2: A phase 2 multi-center study evaluating the efficacy of KTE-C19 (Anti-CD19 CAR T cells) in patients with relapsed/refractory Mantle cell lymphoma (R/R MCL)Presenter: Michael Wang Session: Poster Display Resources: Abstract ZUMA-1: A phase 2 multi-center study evaluating anti-CD19 chimeric antigen receptor (CAR) T cells in patients with refractory aggressive non-Hodgkin lymphoma (NHL)Presenter: Sattva Neelapu Session: Poster Display Resources: Abstract Younger age as a prognostic indicator in breast cancer: Correlation between clinical-pathologic factors and miRNAs and long-term follow-upPresenter: Maria Teresa Martinez Session: Poster display Resources: Abstract Window study of the PARP inhibitor rucaparib in patients with primary triple negative or BRCA1/2 related breast cancer (RIO)Presenter: Christy Toms Session: Poster display Resources: Abstract Whole exome sequencing (WES) and RNA sequencing (RNA-seq) in routine clinical practice for colorectal cancer (CRC) and non-small cell lung cancer (NSCLC) patients (pts)Presenter: Géraldine Perkins Session: Poster display Resources: Abstract What is the optimal annual interpretive volume for a radiologist reading screening mammograms?Presenter: Asli Uluturk Session: Poster display Resources: Abstract What decides breast conservation versus mastectomy in the background of diverse sociocultural environment, an Indian studyPresenter: Poonamalle Padmanabhan Bapsy Session: Poster display Resources: Abstract Waiting time to diagnosis and treatment of the head and neck cancer in four institutions in PortugalPresenter: Ana Castro Session: Poster display Resources: Abstract Wait times for diagnosis and treatment of lung cancer: a single centre experiencePresenter: Catherine Labbe Session: Poster Display Resources: Abstract This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used. For more detailed information on the cookies we use, please check our Privacy Policy.
|